Hovione expands nasal drug delivery capability with IDC partnership

Hovione, a specialist integrated CDMO in spray drying and particle engineering, has expanded its nasal drug delivery capabilities with the addition of a family of nasal powder delivery devices developed in partnership with IDC. 

Intranasal drug delivery is an alternative to conventional delivery routes for both local and systemic drug delivery due to its simplicity, safety, and faster onset of action.

Hovione and IDC have been working together to accelerate the development and commercialisation of two new active nasal powder delivery devices, one single-use and one multidose. The devices enable broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. By using standard capsules and filling equipment, they also have the potential to simplify drug product development and manufacturing.

Dr. Jean-Luc Herbeaux, Hovione's CEO, said: "Intranasal drug delivery is gaining momentum across a number of applications, including mucosal vaccination and CNS treatments bypassing the blood-brain barrier. Our partnership with IDC, a company with vast experience in industrial design, mechanical and electronic engineering of medical devices, enables Hovione to offer a complete solution for nasal powder delivery – covering Active Pharma Ingredients (APIs), formulation, filling, analytics and device design and manufacturing - that address the needs of pharmaceutical companies and patients."

IDC managing director, Dr Stephen Knowles, added: “By combining Hovione’s capabilities in pharmaceutical development, formulation and manufacturing with IDC’s device development expertise, this partnership offers customers a nasal powder delivery solution which can be rapidly adapted to new pharma compounds and therapies. Our joint development team has done incredible work to create unique, high performance nasal powder delivery devices."